In a preclinical trial with an AF pig model, inhibition of atrial-specific K2P3.1 current using the TASK-1 channel blocker A293 reverses pathologic AF-related atrial action potential shortening and significantly prolongs atrial ERP without causing ventricular arrhythmias (Wiedmann et al., 2020). Here, KCNK3 is linked to atrial fibrillation.